Belimumab - Biologic Drug Details

Summary for belimumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for belimumab

Recent Clinical Trials for belimumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
West China Hospital	EARLY_PHASE1
Nanjing University School of Medicine	PHASE2
Assistance Publique - Hpitaux de Paris	PHASE3

See all belimumab clinical trials

Pharmacology for belimumab

Mechanism of Action	B Lymphocyte Stimulator-directed Antibody Interactions
Physiological Effect	Decreased B Lymphocyte Activation
Established Pharmacologic Class	B Lymphocyte Stimulator-specific Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for belimumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for belimumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370	7,879,328	2025-02-10	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	BENLYSTA	belimumab	Injection	761043	7,879,328	2025-02-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for belimumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370	10,017,762	2037-04-26	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370	10,111,968	2036-08-10	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370	10,132,813	2032-02-10	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370	10,259,859	2036-08-05	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370	10,273,252	2036-06-14	Patent claims search

Market Dynamics and Financial Trajectory for Belimumab

Last updated: April 22, 2026

What is the Commercial Profile of Belimumab?

Belimumab is a monoclonal antibody that targets B-lymphocyte stimulator (BLyS), approved for systemic lupus erythematosus (SLE). Made by GlaxoSmithKline (GSK), it generated $1.4 billion globally in 2022, representing approximately 10% of GSK’s immunology sector revenue.

How Does Belimumab Position in the Lupus Treatment Landscape?

Belimumab was the first biologic approved specifically for SLE in 2011, a market historically dominated by corticosteroids and immunosuppressants. Currently, it holds a leading position among biologics for SLE but faces competition from emerging therapies including:

• Anifrolumab (regulatory approval pending or granted in certain regions)
• Voclosporin (approved for lupus nephritis)
• Generic immunosuppressants

In 2022, the global SLE market reached $3.2 billion, with biologics accounting for roughly 45%. Belimumab’s share of this segment is close to 44%, affirming its dominant role.

What Are the Growth Drivers and Barriers?

Growth Drivers

• Expanding Indications: Additional approvals for lupus nephritis and non-renal SLE extend market reach.
• Patient Population Growth: SLE affects approximately 5 million globally; rising awareness and diagnosis improve treatment accessibility.
• Compliance and Administration Form: Injectable form limitations are offset by its proven efficacy and safety, particularly in severe cases.
• Market Access: Increasing coverage by health insurers facilitates uptake in key markets (U.S., EU, China).

Barriers

• Pricing and Reimbursement: High costs ($35,000–$45,000 per year) restrict access in low- and middle-income countries.
• Competition: New therapies in late-stage development threaten to erode its market share.
• Patient Preference: Subcutaneous alternative (belimumab-SC) gains favor over intravenous dosing.

How Has Belimumab’s Revenue Evolved?

Year	Global Revenue (USD millions)	Notes
2016	644	First full year post-approval
2018	1,082	Steady growth driven by expanded indications
2020	1,297	Impact of COVID-19 on treatment access
2022	1,400	Mature market with stable growth

The compound annual growth rate (CAGR) from 2016 to 2022 is approximately 20%.

What Are Market Outlook Projections?

Forecasts project belimumab revenues will reach between $2 billion and $2.5 billion globally by 2027, driven by:

• Greater adoption in EU, China, and emerging markets.
• Approval of new formulations (subcutaneous delivery in 2021).
• Label expansion for lupus nephritis in major markets (FDA, EMA decisions from 2023 onwards).

However, these projections face uncertainties stemming from regulatory policies, pricing pressures, and competitive innovations.

How Are Regulatory Agencies Influencing Belimumab?

• FDA: Approved belimumab for active, autoantibody-positive SLE in 2011; expanded to lupus nephritis in 2021.
• EMA: Approved for SLE in 2011; approved for lupus nephritis in 2020.
• China NMPA: Approved in 2022, boosting sales in Asia-Pacific.

Regulatory decisions influence market access and reimbursement conditions, impacting revenue streams.

What Is the Investment Outlook?

Belimumab’s outlook remains favorable for GSK, considering:

• A stable, growing market for SLE treatments.
• Opportunity in expanding indications.
• Increasing pipeline of combination therapies and formulations.

Potential risks include patent expiry timelines (expected post-2030), pricing reforms, and the emergence of biosimilars.

Key Financial Data Summary

Metric	2022 Data	Source
Global Revenue	$1.4 billion	GSK annual report
Market Share (Biologics in SLE)	44%	IQVIA, 2022
Average Price per Year	$35,000–$45,000	Market estimates

Key Takeaways

• Belimumab maintains a leading position in the SLE biologics market, contributing significant revenues for GSK.
• Growth is driven by new indications, approvals, and emerging markets, but faces competition from newer therapies and biosimilars.
• Market expansion hinges on regulatory approvals, reimbursement landscapes, and formulation enhancements.
• The expected revenue trajectory suggests stabilization but with moderate growth potential approaching 2027.

FAQs

1. When will biosimilars for belimumab enter the market?
Likely post-2030, corresponding with patent expiration windows. Currently, patent protections extend into the early 2030s.

2. What are the key competitors to belimumab in SLE?
Anifrolumab (FDA approved), voclosporin (lupus nephritis), and emerging biosimilars.

3. How does belimumab compare cost-wise with traditional SLE therapies?
Significantly higher; traditional immunosuppressants cost approximately $5,000–$10,000 annually.

4. What are the main regulatory hurdles for expanding belimumab indications?
Demonstrating efficacy in new subsets of SLE and lupus nephritis, and navigating regional approval processes.

5. What market segments are most critical for belimumab’s future growth?
Lupus nephritis in North America and China, plus biologics treatment in under-served regions.

---

References

[1] GSK. (2023). Annual Report. Retrieved from https://www.gsk.com/en-gb/investors/reports-results-and-presentations/
[2] IQVIA. (2022). Global Lupus Market Report.
[3] FDA. (2021). Approval Letter for Lupus Nephritis Indication.
[4] EMA. (2020). Pharmacovigilance and Market Authorization Documentation for Belimumab.
[5] Chinese NMPA. (2022). Approval Announcement for Belimumab.